Glycopyrrolate Oral Solution, 1 mg/5 mL recall — Precision Dose Inc. (Class II)

Precision Dose Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Glycopyrrolate Oral Solution, 1 mg/5 mL — a Class II recall, initiated 2026-07-14 and posted to the FDA enforcement report on 2026-07-29, under recall number D-0741-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Impurities/Degradation Specifications”. From the product description, the form is oral solution, the strengths given are 1 mg/5 mL and 5 mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 68094-073-01. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in IL, United States. It is the only recall number the FDA has filed under event ID 99388. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0741-2026
FDA event ID 99388
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Precision Dose Inc.
Recall initiated 2026-07-14
Reported by FDA 2026-07-29
Report lag 15 days from initiation to report
Distribution US Nationwide. — Nationwide (US)
Firm location on record IL, United States
Product description (source) Glycopyrrolate Oral Solution, 1 mg/5 mL, delivers 5 mL, Rx only, Pkg: Precision Dose, Inc, S. Beloil, IL 61080, unit-dose oral syringes, NDCs 68094-073-01 (oral syringe) and 68094-073-58 (case).

Reason reported by FDA

Failed Impurities/Degradation Specifications

3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

5 identifying values matched by exact pattern in the 29-word product description above; each is a literal substring of it.

Product named Glycopyrrolate Oral Solution
Form Oral Solution
Strength 1 mg/5 mL · 5 mL
NDC s: 68094-073-01
Marketing category Rx only

Other indexed recalls of glycopyrrolate

2 indexed records name glycopyrrolate as the recalled substance. Matching is on the product-name prefix of the FDA's own text, so other strengths and packages are included.

Recall recordRecall numberRecalling firmStrength / formReported
Glycopyrrolate Injection, 1 mgD-0725-2026Fresenius Kabi Usa, LLC1 mg · Injection2026-07-29

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Levothyroxine Sodium Tablets, 25 mcgD-0700-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0701-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0702-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 88 mcgD-0703-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 112 mcgD-0704-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0705-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0706-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 25 mcgD-0707-2026Major PharmaceuticalsClass II2026-07-29

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 7 nearest to 2026-07-29 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Levothyroxine Sodium Tablets, 50 mcgD-0708-2026Major Pharmaceuticals50 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0709-2026Major Pharmaceuticals75 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0710-2026Major Pharmaceuticals125 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0711-2026Major Pharmaceuticals150 mcg · Tablets2026-07-29
Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mgD-0712-2026Ascend Laboratories, LLC10 mg/20 mg · Tablets2026-07-29
Rohto Cooling Eye Drops ALL-IN-ONE, 0.2%D-0715-2026Rohto-mentholatum (vietnam) Co., Ltd.0.2% · Eye Drops2026-07-29
Rohto Cooling Eye Drops Max Strength, 0.03%D-0716-2026Rohto-mentholatum (vietnam) Co., Ltd.0.03% · Eye Drops2026-07-29

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 68094-073-01 (s) at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Precision Dose Inc. (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0741-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0741-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-29
Ingested
2026-08-22
Record hash
64fce23a4c598dbb

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.